ACHP Statement on “Most-Favored-Nation” Rx Pricing Executive Order
ACHP released a statement on the most-favored-nation prescription drug pricing executive order.
ACHP released a statement on the most-favored-nation prescription drug pricing executive order.
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
ACHP comments on the CMS Marketplace Integrity and Affordability Proposed Rule.
ACHP commends the Trump Administration for finalizing policies in the 2026 MA and Part D Rate Notice that reflect higher care delivery costs and for taking another step toward reining in aggressive risk adjustment to boost competition.
ACHP sent a letter to CMS Administrator, Dr. Oz, with proposed legislation.
